Canada

Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness

MS-2-802, Box 23, Folder 10
File
2000

File contains abstracts, a poster presentation, notes and tables.

Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies

MS-2-802, Box 24, Folder 3
File
2019

Part of Murray G. Brown fonds

File contains manuscript draft and submission correspondence to Journal of Clinical Epidemiology.

National Multiple Sclerosis Society (NMSS) COSTRIMS study

MS-2-802, Box 23, Folder 4
File
2006

Part of Murray G. Brown fonds

File includes a draft project outline sent to Katia Noyes, principal investigator from the University of Rochester; a printed PowerPoint presentation; and handwritten notes.

Murray G. Brown fonds

MS-2-802
Fonds
1970 - 2019

Fonds comprises Murray Brown's research and teaching-related records, including notes, annotated drafts of papers, presentations and reports, abstracts, correspondence, funding applications and reports, as well as administrative papers and employment records and contracts.

Brown, Murray G.

Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual

MS-2-802, Box 23, Folder 9
File
2000 - 2009

Part of Murray G. Brown fonds

File contains a copy of the user manual and related memos, abstracts, correspondence and a presentation.

Multiple sclerosis net benefits feasibility study

MS-2-802, Box 23, Folder 3
File
2002 - 2006

Part of Murray G. Brown fonds

File includes funding proposal and correspondence.

Multiple Sclerosis Integrated Database (MSID) datasets

MS-2-802, Box 21, Folder 3
File
2003

Part of Murray G. Brown fonds

Multiple sclerosis disease-modifying drug and health care costs in Nova Scotia, 1989 -2003 / Vern Hicks, Murray G. Brown, I.S. Sketris

MS-2-802, Box 25, Folder 8
Item
2006

Part of Murray G. Brown fonds

File includes a manuscript marked VH (Vernon Hicks) Dec 3 and related email correspondence.

MS cost-effectiveness study correspondence and meeting notes

MS-2-802, Box 25, Folder 1
File
2003

Part of Murray G. Brown fonds

Modelling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying drugs that delay disability progression

MS-2-802, Box 23, Folder 5
Item
2010

Part of Murray G. Brown fonds

Item is an abstract submitted to the Canadian Congress of Neurological Sciences 45th annual scientific meeting .

Information sinkholes on the road to representative estimates of MS disability progression speed ....

MS-2-802, Box 24, Folder 4
Item
2014

Part of Murray G. Brown fonds

File contains a copy of a presentation made at the endMS Knowledge Exchange, April 10, 2014, in Halifax, Nova Scotia.

How effective are new drugs in delaying disability progression in relapsing remitting onset multiple sclerosis? A subgroup analysis

MS-2-802, Box 25, Folder 11
Item
2006

Part of Murray G. Brown fonds

Item is a draft manuscript by Murray brown, Sarah Kirby, Chris Skedgel, John D. Fisk, Donna MacKinnon-Cameron, T. Jock Murray, Virender Bhan and Ingrida S. Sketris.

First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data

MS-2-802, Box 24, Folder 2
File
2019

Part of Murray G. Brown fonds

File contains manuscript draft and submission correspondence to PharmacoEconomics.

Evaluation of health-related quality of life utility measures in patients with multiple sclerosis

MS-2-802, Box 23, Folder 11
File
2000

Part of Murray G. Brown fonds

File contains a report prepared by John D. Fisk for the Dalhousie University Multiple Sclerosis Research Group with appended notes from Murray Brown.

Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data

MS-2-802, Box 21, Folder 1
File
2011 - 2012

Part of Murray G. Brown fonds

File contains contracts, outlines, abstracts, correspondence, reports and other records relating to the 2012 Sanofi-Ventis study.

Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data

MS-2-802, Box 20, Folder 5
File
2011 - 2018

Part of Murray G. Brown fonds

File contains Research Ethics Board submission records for the Sanofi-Ventis study.

Email between Sarah Kirby and Murray Brown regarding modelling for research on drug efficacy in delaying disability progression in relapsing remitting onset MS

MS-2-802, Box 25, Folder 12
File
2006

Part of Murray G. Brown fonds

Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada

MS-2-802, Box 24, Folder 1
File
2004, 2006

Part of Murray G. Brown fonds

File also contains a 2006 draft copy of "How Effective are New Drugs in Delaying Disability Progression in Multiple Sclerosis? or Effectiveness of Multiple Sclerosis Drugs in the 'real world': Nova Scotia Evidence."

Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report

MS-2-802, Box 23, Folder 12
File
2004 - 2012

Part of Murray G. Brown fonds

File contains a draft outline of the final report, dated September 2004, and copies of related studies, tables, figures, posters, presentations, etc. dated up to 2012.

Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"

MS-2-802, Box 20, Folders 3 and 4
File
2004

Part of Murray G. Brown fonds

File contains a draft outline of the final report published by Brown et al., Dalhousie MS Research Unit; 12 sub studies; dissemination of methods and results; and the final report to the Nova Scotia Health Research Foundation of the Nova Scotia Multiple Sclerosis Integrated Database (MS MSID) Update Project. The records were removed from a three-rind binder and separated into two folders.

EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004

MS-2-802, Box 22, Folder 2
File
2006

Part of Murray G. Brown fonds

File includes drafts of the paper, correspondence, including submission correspondence, notes, abstracts, tables and graphs, and offprints of related published work.

Dalhousie MS Research Group meeting minutes

MS-2-802, Box 21, Folder 2
File
2003

Part of Murray G. Brown fonds

File includes correspondence, reports and other records related to the MSID (Multiple Sclerosis Integrated Database) Update Project and the MS Real World Study.

Cost-effectiveness of multiple sclerosis drugs in the "real world"

MS-2-802, Box 23, Folder 1
File
2005 - 2006

Part of Murray G. Brown fonds

File includes two presentations of the research findings: at the Canadian Association of Health Services and Policy Research Conference in Montreal, September 16-18, 2005; and at the Conference at the Centre for Health Services and Policy Research (CHSPR), UBC, February 9-10, 2006.

Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates

MS-2-802, Box 23, Folder 6
File
1996, 2000

Part of Murray G. Brown fonds

File includes a one-page summary and an offprint of an overview based in part on the CCOHTA study conducted by Murray Brown et al.

Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS

MS-2-802, Box 23, Folder 2
File
2005 - 2006

Part of Murray G. Brown fonds

File includes two (PowerPoint) presentations of the research findings: at the DMSRU Study Group seminar on 14 December 2005; and at UBC Department of Neurology on February 8, 2006.

Benign multiple sclerosis : a 25-year retrospective analysis and redefinition

MS-2-802, Box 22, Folder 6
File
2004

Part of Murray G. Brown fonds

File includes a proposal for a study by Jock Murray and the Dalhousie MS Research Unit Study Group and related correspondence with Teva Neuroscience, Canada.

Subject

Genre

Taxonomy

Code

Scope note(s)

Source note(s)

Display note(s)

Hierarchical terms

Canada

Canada

Equivalent terms

Canada

Associated terms

Canada

26 Archival Description results for Canada

Export

Results

Broader term

No. narrower terms